Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial by Jean E. Abraham, Lenka Oplustil O’Connor, Louise Grybowicz, Karen Pinilla Alba, Alimu Dayimu, Nikolaos Demiris, Caron Harvey, Lynsey M. Drewett, Rebecca Lucey, Alexander Fulton, Anne N. Roberts, Joanna R. Worley, Ms Anita Chhabra, Wendi Qian, Jessica Brown, Richard Hardy, Anne-Laure Vallier, Steve Chan, Maria Esther Una Cidon, Elizabeth Sherwin, Amitabha Chakrabarti, Claire Sadler, Jen Barnes, Mojca Persic, Sarah Smith, Sanjay Raj, Annabel Borley, Jeremy P. Braybrooke, Emma Staples, Lucy C. Scott, Cheryl A. Palmer, Margaret Moody, Mark J. Churn, Domenic Pilger, Guido Zagnoli-Vieira, Paul W. G. Wijnhoven, Mukesh B. Mukesh, Rebecca R. Roylance, Philip C. Schouten, Nicola C. Levitt, Karen McAdam, Anne C. Armstrong, Ellen R. Copson, Emma McMurtry, Susan Galbraith, Marc Tischkowitz, Elena Provenzano, Mark J. O’Connor, Helena M. Earl, PARTNER Trial Group

Get full text